Trials / Completed
CompletedNCT04350021
Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer
Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer - a Two Step Study With a Retrospective Analyses Followed by a Translational Phase II Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (actual)
- Sponsor
- Vastra Gotaland Region · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Low dose metronomic chemotherapy (LDMC) in patients with metastatic breast cancer (MBC) is used as a palliative regiment with the aim to prolong and improve quality of life. The effect of LDMC is not fully elucidated. The aim is to evaluate the effect of LDMC with Capecitabine and Cyclophosphamide (CX) and to discover new potential predictive markers and potential markers for monitoring treatment effect.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capecitabine, Cyclophosphamide | Capecitabine 500 mg times three, Cyclophosphamide 50 mg once daily |
Timeline
- Start date
- 2019-03-01
- Primary completion
- 2023-10-30
- Completion
- 2023-10-30
- First posted
- 2020-04-16
- Last updated
- 2024-01-17
Locations
1 site across 1 country: Sweden
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04350021. Inclusion in this directory is not an endorsement.